Patents Assigned to Jenrin Discovery, Inc.
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 9987253
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 5, 2018
    Assignee: JENRIN DISCOVERY, INC.
    Inventors: John F McElroy, Robert J Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 9517228
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 13, 2016
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F McElroy, Robert J Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
    Patent number: 9133127
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: September 15, 2015
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8853252
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: October 7, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • 4-quinolinemethanols as anti-malarial agents
    Patent number: 8716265
    Abstract: The present invention relates to substituted 4-qinolinemethanols and pharmaceutical compositions thereof and methods of using the same for treating of malaria, tuberculosis, and other infectious diseases.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 6, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat, David Nugiel
  • Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
    Patent number: 8680131
    Abstract: The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: March 25, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John Francis McElroy, Robert John Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8648072
    Abstract: The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 11, 2014
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8580768
    Abstract: The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: November 12, 2013
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F McElroy, Robert J Chorvat
  • MAO-B inhibitors useful for treating obesity
    Patent number: 8541475
    Abstract: The invention provides novel compounds of formulae I and II: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: September 24, 2013
    Assignee: Jenrin Discovery, Inc.
    Inventors: John Francis McElroy, Robert J. Chorvat, Parthasarathi Rajagopalan
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8334282
    Abstract: The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: December 18, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Purine compounds as cannabinoid receptor blockers
    Patent number: 8252791
    Abstract: The present invention relates to purine-based cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, inflammatory disorders, hepatic disorders, and a combination thereof.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: August 28, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 8236821
    Abstract: The present invention provides novel pyrazolines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: August 7, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8217038
    Abstract: The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: July 10, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Substituted picolinamides as MAO-B inhibitors useful for treating obesity
    Patent number: 8138209
    Abstract: The invention provides novel compounds of formula I: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: March 20, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John Francis McElroy, Robert J. Chorvat, Rajagopalan Parthasarathi
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8138216
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: March 20, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 8133904
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: March 13, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • MAO inhibiting N-benzyl-N-propargyl-amines useful for treating obesity
    Patent number: 8124802
    Abstract: The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: February 28, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 8088926
    Abstract: The present invention provides novel substituted 2-methyl-2-phenoxy-N-propyl-propionamides and derivatives thereof that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: January 3, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
    Patent number: 8088809
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: January 3, 2012
    Assignee: Jenrin Discovery, Inc.
    Inventors: John F. McElroy, Robert J. Chorvat
  • Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
    Patent number: 7687481
    Abstract: The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: March 30, 2010
    Assignee: Jenrin Discovery, Inc.
    Inventors: John Francis McElroy, Robert J. Chorvat